Once-Daily Cetirizine Is Safe and Effective for Children with Allergic Rhinitis with and without Intermittent Asthma

Segal, Allen T.; Meltzer, Eli O.; Lockey, Richard F.; Prenner, Bruce M.; Mitchell, Don Q.; Tinkelman, David G.; Hewlett, Dial; Chapman, Douglass; Krämer, Benjamin

doi:10.1089/088318703322751318

Cited by 8 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies included school-aged children, and seven publications included children ≤24 months-old. 20,25,27,31,35,43,44 The most frequent type of condition that required the use of antihistamines was allergic rhinitis, [13][14][15][17][18][19][20][21]23,24,26,[28][29][30][32][33][34][35][36][39][40][41][42][45][46][47][48][49][50][51][52][55][56][57][58] followed by chronic idiopathic urticaria 15,20,30,35,38,42 and atopic dermatitis. 25,35,37,…”

Section: Study Characteristicsmentioning

confidence: 99%

“…25,35,37,43,44,54 The majority of studies did not provide any evidence regarding concomitant medications, and ten studies reported inclusion of patients with concomitant asthma. 16,17,28,33,34,40,47,[52][53][54] Cetirizine was administered in 22 studies, 14,21,26,32,[34][35][36]38,40,45,[47][48][49][50][51][52][53][54][55][56][57][58] loratadine in 10 studies, 14,18,31,37,39,42,46,47,59 levocetirizine in 6 studies, [19][20][21]2...…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Newer‐generation antihistamines and the risk of adverse events in children: A systematic review

Miligkos

Dakoutrou

Statha³

et al. 2021

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Background: H1-antihistamines (AHs) are widely used for the treatment of allergic diseases, being one of the most commonly prescribed classes of medications in pediatrics. Newer-generation AHs are associated with fewer adverse effects compared with first-generation AHs. However, their relative harms in the pediatric population still need scrutiny. Methods:We performed a systematic review of randomized controlled trials (RCTs), which included comparisons of safety parameters between an orally administered newer-generation AH and another AH (first-or second-generation), montelukast, or placebo in children aged ≤12 years. We searched MEDLINE and CENTRAL, independently extracted data on study population, interventions, adverse events (AEs), and treatment discontinuations, and assessed the methodologic quality of the included RCTs using the Cochrane's risk of bias tool.Results: Forty-five RCTs published between 1989 and 2017 met eligibility criteria.The majority of RCTs included school-aged children with allergic rhinitis and had a follow-up period of up to a month. Four RCTs reported serious AEs in patients receiving a newer-generation AH, but only two patients experienced a possibly drug-related serious AE. The occurrence of AEs, drug-related AEs, and treatment discontinuations due to AEs varied between RCTs. Most AEs reported were of mild intensity. Indirect evidence indicates that cetirizine is more sedating than the other newer-generation AHs. Conclusion:Our findings confirm that newer-generation AHs have a favorable safety and tolerability profile. However, we could not draw firm conclusions regarding the comparative safety profile of the newer-generation AHs due to the paucity of head-tohead RCTs, variation in definitions and reporting of AEs, and short follow-up duration.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Newer‐generation antihistamines and the risk of adverse events in children: A systematic review

Miligkos

Dakoutrou

Statha³

et al. 2021

Pediatric Allergy Immunology

View full text Add to dashboard Cite

show abstract

“…The most frequent type of condition that required the use of antihistamines was allergic rhinitis 13,14,15, 17-21"23,24,26,28-30,32-36,39-42,45-52,55-58 , followed by chronic idiopathic urticaria 15,20,30,35,38,42 and atopic dermatitis 25,35,37,43,44,54 . The majority of studies did not provide any evidence regarding concomitant medications and ten studies reported inclusion of patients with concomitant asthma 16,17,28,33,34,40,47,[52][53][54] . Cetirizine was administered in 22 studies 14,21,26,32,[34][35][36]38,40,45,[47][48][49][50][51][52][53][54][55][56][57][58] , loratadine in 10 studies 14,18,31,37,39,42...…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The majority of studies did not provide any evidence regarding concomitant medications and ten studies reported inclusion of patients with concomitant asthma 16,17,28,33,34,40,47,[52][53][54] . Cetirizine was administered in 22 studies 14,21,26,32,[34][35][36]38,40,45,[47][48][49][50][51][52][53][54][55][56][57][58] , loratadine in 10 studies 14,18,31,37,39,42,[46][47]59 , levocetirizine in 6 studies [19][20][21]25,28,29 , fexofenadine in 4 studies 23,24,33,41 , desloratadine in 4 studies 13,…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Newer-generation antihistamines and the risk of adverse events in children: a systematic review

Miligkos

Dakoutrou

Statha³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: H1-antihistamines (AHs) are widely used for the treatment of allergic diseases, being one of the most commonly prescribed classes of medications in Pediatrics. Newer-generation AHs are associated with fewer adverse effects compared to first-generation. However, their relative harms in the pediatric population still need scrutiny. Methods: We performed a systematic review of randomized controlled trials (RCTs) which included comparisons of safety parameters between an orally administered newer-generation AH with another AH (first- or second- generation), montelukast or placebo in children aged≤12 years. We searched MEDLINE and CENTRAL, independently extracted data on study population, interventions, adverse events (AEs) and treatment discontinuations, and assessed the methodological quality of the included RCTs using the Cochrane’s risk of bias tool. Results: Fourty-five RCTs published between 1989 and 2017 met eligibility criteria. The majority of RCTs included school-aged children with allergic rhinitis and had a follow-up period of up to a month. Four RCTs reported serious AEs in patients receiving a newer-generation AH, but only two patients experienced a possibly drug-related serious AE. The occurrence of AEs, drug-related AEs and treatment discontinuations due to AEs varied between RCTs. Most AEs reported were of mild intensity. Indirect evidence indicates that cetirizine is more sedating than the other newer-generation AHs. Conclusion: Our findings confirm that newer-generation AHs have a favorable safety and tolerability profile. However, we could not draw firm conclusions regarding the comparative safety profile of the newer-generation AHs due to the paucity of head-to-head RCTs, variation in definitions and reporting of AEs, and short follow-up duration.

show abstract

Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults

Chauhan

Chartrand

Ducharme

2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Once-Daily Cetirizine Is Safe and Effective for Children with Allergic Rhinitis with and without Intermittent Asthma

Cited by 8 publications

References 19 publications

Newer‐generation antihistamines and the risk of adverse events in children: A systematic review

Newer‐generation antihistamines and the risk of adverse events in children: A systematic review

Newer-generation antihistamines and the risk of adverse events in children: a systematic review

Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults

Contact Info

Product

Resources

About